U.S. HLA Typing for Transplant Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

HLA Typing for Transplant Market Size

• The U.S. HLA Typing for Transplant market size was valued at USD 1.41 billion in 2025 and is expected to reach USD 3.13 billion by 2033, at a CAGR of 10.50% during the forecast period
• The market growth is largely fueled by the increasing prevalence of organ and stem cell transplants worldwide, coupled with the critical need for accurate HLA typing to ensure donor-recipient compatibility and reduce the risk of transplant rejection. Advances in molecular diagnostics, automation, and high-throughput sequencing technologies are further enhancing the efficiency and precision of HLA typing, driving market adoption
• Furthermore, rising awareness among healthcare providers and patients regarding the importance of immunogenetic matching, along with increasing investments in transplant programs and precision medicine initiatives, is establishing HLA Typing for Transplant solutions as an essential tool in modern transplant management. These converging factors are accelerating the uptake of HLA typing solutions, thereby significantly boosting the industry’s growth

HLA Typing for Transplant Market Analysis

• HLA Typing for Transplant solutions, offering precise donor-recipient compatibility testing for organ and stem cell transplants, are increasingly vital components of modern transplant management systems in both hospitals and specialized diagnostic laboratories due to their enhanced accuracy, faster turnaround times, and integration with automated molecular diagnostic platforms
• The escalating demand for HLA Typing for Transplant is primarily fueled by the growing number of organ and stem cell transplants, rising awareness regarding immunogenetic matching, and increasing adoption of advanced molecular and high-throughput sequencing technologies
• The U.S. dominated the HLA Typing for Transplant market with the largest revenue share in 2025, driven by advanced healthcare infrastructure, high number of organ and stem cell transplants, strong adoption of molecular diagnostics, and the presence of leading HLA typing solution providers
• The molecular assay technologies segment dominated the market with a revenue share of around 55.6% in 2025, driven by the high precision, sensitivity, and reliability of DNA-based testing methods such as PCR, NGS, and SSO

Report Scope and HLA Typing for Transplant Market Segmentation  

HLA Typing for Transplant Market Trends

Growing Adoption of Advanced Molecular and Genotyping Techniques

• A significant trend in the HLA Typing for Transplant market is the rising use of high-resolution molecular typing techniques, including next-generation sequencing (NGS) and PCR-based methods, which provide accurate and detailed HLA profiles for both donors and recipients
  • For instance, the Mayo Clinic in the U.S. implemented NGS-based HLA typing for bone marrow transplants, reducing ambiguities in donor-recipient matching and improving transplant success rates. Similarly, European transplant centers have adopted multiplex PCR platforms for faster, reliable typing in urgent cases
• The trend toward automation and high-throughput processing is enabling laboratories to handle larger donor pools and reduce manual errors, accelerating the overall transplant workflow
• Integration of bioinformatics and AI-driven data analysis allows for precise interpretation of complex HLA allele variations, facilitating personalized transplant planning
• Increasing collaboration among global donor registries and laboratories is driving standardization of HLA typing protocols, improving compatibility matching for international transplants

HLA Typing for Transplant Market Dynamics

Driver

Increasing Number of Organ and Stem Cell Transplants

• Rising prevalence of chronic diseases, hematologic disorders, and organ failures is driving demand for accurate HLA typing, as precise matching is critical to reduce graft rejection and post-transplant complications
  • For instance, in 2024, the National Marrow Donor Program (NMDP) in the U.S. recorded a surge in bone marrow transplants among leukemia patients, leading hospitals to adopt rapid, high-resolution HLA typing platforms to ensure timely donor-recipient matches. Similarly, Japan’s leading cardiac and hematology centers have integrated automated HLA typing workflows to meet growing transplant demand
• The expansion of national and regional donor registries is increasing the need for standardized, high-quality HLA typing services to manage large volumes of donor-recipient matches efficiently
• Technological innovations such as microarray-based HLA typing and fully automated sequencing are enhancing laboratory efficiency, reducing turnaround times, and supporting high-volume transplant programs
• Rising awareness among clinicians and patients about the importance of HLA compatibility is increasing adoption rates of advanced typing services, particularly in specialized hospitals and transplant centers

Restraint/Challenge

High Cost of Advanced HLA Typing and Limited Accessibility

• The high cost of advanced HLA typing platforms such as next-generation sequencing (NGS) and automated PCR systems remains a significant barrier, particularly for smaller hospitals, diagnostic centers, and healthcare facilities in developing regions. These high upfront costs can deter adoption despite the clinical benefits of high-resolution typing
  • For instance, in India, many regional hospitals still rely on conventional serological HLA typing due to budget constraints, which may lead to lower match accuracy and a higher risk of graft rejection compared to high-resolution molecular methods
• The requirement for skilled laboratory personnel poses a challenge, as operating advanced HLA platforms requires specialized training in molecular biology, sequencing, and bioinformatics. Many regions face a shortage of trained technicians, leading to delays in testing and potential errors in results
• Infrastructure limitations such as inadequate laboratory space, outdated equipment, insufficient quality control protocols, and limited maintenance support can further impede efficient HLA typing operations. These constraints are particularly evident in community hospitals and smaller diagnostic labs
• Regulatory and compliance challenges across different countries add complexity to market expansion. Laboratories must adhere to stringent quality and accreditation standards, such as ISO 15189 and CAP (College of American Pathologists) certification, which can be resource-intensive and time-consuming to implement
• Turnaround time for advanced typing tests can be a limiting factor, especially in urgent transplant cases where rapid donor-recipient matching is critical. While high-resolution typing improves accuracy, longer processing times in under-equipped labs may delay transplantation procedures
• Data management and interoperability issues can arise when integrating HLA typing results with hospital information systems and donor registries. Lack of standardized formats and secure data-sharing protocols may hinder efficient coordination between transplant centers and donor databases
• Limited insurance coverage and reimbursement in certain regions can restrict patient access to advanced HLA typing services. Patients in countries with lower healthcare funding may not be able to afford high-resolution typing, even when it is clinically recommended

HLA Typing for Transplant Market Scope

The HLA Typing for Transplant market is segmented on the basis of product, application, technology, and end user.

• By Product

On the basis of product, the HLA Typing for Transplant market is segmented into reagents and consumables, instruments, and software & services. The reagents and consumables segment dominated the largest market revenue share of around 47.5% in 2025, driven by the recurring requirement of these products in HLA testing procedures. Reagents such as antibodies, primers, and probes are essential for accurate HLA typing and compatibility testing between donors and recipients. Hospitals, diagnostic laboratories, and research centers rely heavily on high-quality consumables to ensure precise results and reduce the risk of transplant rejection. The growing number of organ transplant procedures worldwide has significantly increased the demand for reagents and consumables. In addition, technological advancements in molecular assay kits and high-throughput testing methods are enhancing reagent efficiency and accuracy. The adoption of automated platforms in laboratories further supports reagent consumption, as these systems require continuous supplies of specialized consumables. The increasing awareness of transplant compatibility testing and government initiatives to improve organ donation programs also boost segment growth. Reagents and consumables are widely used across diagnostic, research, and clinical applications, maintaining their dominant market position. Furthermore, the recurring expenditure on these products ensures steady revenue generation for manufacturers.

The instruments and software & services segment is expected to witness the fastest CAGR of 8.2% from 2026 to 2033, driven by the rising adoption of advanced HLA typing platforms and bioinformatics tools. Instruments such as PCR machines, sequencers, and automated analyzers are increasingly used in modern laboratories to enhance testing speed and accuracy. Software solutions support data management, interpretation, and reporting, improving overall laboratory efficiency. Research and clinical laboratories are adopting integrated systems combining hardware and software for high-throughput HLA typing. Furthermore, growing investments in molecular diagnostics and bioinformatics are driving demand for these solutions. The rising number of complex transplant procedures requiring precise donor-recipient matching is also contributing to segment growth. Academic institutions and research labs are increasingly utilizing software and services for translational research in transplantation immunology. In addition, cloud-based services and AI-assisted data analysis are enhancing the adoption of software solutions in HLA typing workflows. As hospitals and diagnostic centers upgrade to modern platforms, this segment is expected to grow rapidly over the forecast period.

• By Application

On the basis of application, the HLA Typing for Transplant market is segmented into diagnostic applications, donor-recipient cross-matching, infectious disease testing, cancer diagnosis and prevention, transfusion therapy, other diagnostic applications, and research applications. The donor-recipient cross-matching segment held the largest market revenue share of approximately 39.2% in 2025, primarily due to its critical role in organ transplantation. Accurate cross-matching ensures compatibility between donors and recipients, minimizing the risk of transplant rejection and improving post-transplant outcomes. The increasing number of organ transplant procedures worldwide is driving the demand for HLA typing in cross-matching applications. Hospitals and specialized transplant centers rely on molecular and non-molecular HLA typing technologies to evaluate donor-recipient compatibility efficiently. Technological advancements in high-resolution typing methods have improved accuracy, further supporting segment growth. Government initiatives promoting organ donation programs and awareness about transplantation safety also boost adoption. In addition, the rising prevalence of chronic kidney disease, liver failure, and other organ disorders is increasing the demand for transplant procedures. The segment benefits from recurring testing needs for pre- and post-transplant patient monitoring. As transplantation procedures continue to grow globally, donor-recipient cross-matching remains the leading application in the market.

がんの診断と予防分野は、免疫療法や個別化がん治療におけるHLAタイピングの利用拡大を背景に、2026年から2033年にかけて年平均成長率（CAGR）8.5%と最も高い成長が見込まれています。HLAタイピングは、個々の免疫プロファイルを理解することで、標的療法や免疫療​​法の対象となる患者を特定するのに役立ちます。世界的ながん罹患率の上昇と精密医療の普及拡大が、HLAベースの診断に対する需要を高めています。学術機関や研究機関は、HLA型とがん感受性との関連性を研究する取り組みをますます積極的に進めており、これがこの分野の成長をさらに後押ししています。さらに、分子アッセイにおける技術進歩により、腫瘍学分野における迅速かつ正確なHLAタイピングが可能になっています。個別化治療と免疫遺伝学への認識が高まるにつれ、がんの診断と予防におけるHLAタイピングの採用は、予測期間中に大幅に増加すると予想されます。

• テクノロジーによって

移植用HLAタイピング市場は、技術に基づいて分子アッセイ技術と非分子アッセイ技術に分類されます。分子アッセイ技術セグメントは、PCR、NGS、SSOなどのDNAベースの検査方法の高い精度、感度、信頼性により、2025年には約55.6%の収益シェアで市場を牽引しました。分子アッセイは高解像度のタイピングを提供し、ドナーとレシピエントの正確なマッチングを可能にし、移植の成功率を向上させます。自動化されたハイスループット検査システムの需要の高まりが、さらなる成長を支えています。病院、移植センター、診断検査機関は、再現性と希少なHLA変異体を検出できる能力から、分子技術を好んでいます。技術の進歩と包括的な分子キットの入手可能性が、世界的な採用を促進しています。さらに、臓器移植の普及率の上昇と免疫遺伝学研究の必要性も、このセグメントの優位性に貢献しています。

非分子アッセイ技術分野は、特定の臨床現場における血清学的検査法およびフローサイトメトリー法の継続的な利用を背景に、2026年から2033年にかけて年平均成長率（CAGR）7.8%と最も高い成長率を示すと予測されています。これらの方法は、迅速スクリーニング、予備的な型判定、および分子アッセイが実施困難な場合に用いられます。非分子アッセイ法は費用対効果が高く、高度な分子プラットフォームへのアクセスが限られている新興国で広く普及しています。自動化された検査ワークフローやハイブリッドアプローチとの統合の進展も、成長を後押ししています。

• エンドユーザーによる

エンドユーザーに基づいて、移植用HLAタイピング市場は、商業サービスプロバイダー、病院および外科センター、研究ラボ、学術機関に分類されます。病院および外科センターセグメントは、臓器移植および関連する診断検査の実施における役割により、2025年には約43.7%という最大の収益シェアで市場を牽引しました。病院は、ドナーとレシピエントのマッチングおよび移植後のモニタリングのために、信頼性の高いHLAタイピングソリューションを必要としています。外科センターおよび病院内の高度なラボは、頻繁な検査をサポートするために、ハイスループット機器と消耗品を備えています。世界的に臓器移植手術が増加し、病院のインフラが改善されていることが、このセグメントの成長に貢献しています。さらに、移植プログラムに対する政府の支援と医療啓発キャンペーンが、臨床現場でのHLAタイピングの採用を促進しています。病院および外科センターは、分子アッセイやソフトウェアツールを含む統合検査ソリューションの優先エンドユーザーであり続けています。

研究機関および学術機関セグメントは、免疫遺伝学、移植生物学、精密医療の研究の高まりを背景に、2026年から2033年にかけて年平均成長率（CAGR）8.3%と最も高い成長率を示すと予想されています。これらの機関は、HLAと疾患の関連性、ドナーとレシピエントの適合性、免疫療法の開発に関する研究を行っています。トランスレーショナルリサーチとバイオテクノロジー革新への資金増加は、高度なHLAタイピング技術への需要を支えています。バイオインフォマティクスとAI支援データ分析を研究ワークフローに統合することで、その普及はさらに加速します。個別化医療、免疫遺伝学、臓器移植研究への関心が高まるにつれ、このセグメントは予測期間中に急速に拡大すると予想されます。

移植におけるHLAタイピングの市場シェア

移植用HLAタイピング業界は、主に以下のような実績のある企業によって牽引されています。

• サーモフィッシャーサイエンティフィック（米国）
• イルミナ社（米国）
• バイオ・ラッド・ラボラトリーズ社（米国）
• BD（米国）
• パーキンエルマー社（米国）
• ホロジック社（米国）
• CareDx, Inc.（米国）
• ワン・ラムダ社（米国）
• アボット・ラボラトリーズ（米国）
• GenDx（オランダ）
• イムコア社（米国）
• オックスフォード・イムノテック社（英国）
• フジレビオ株式会社（日本）
• ルミネックス・コーポレーション（米国）
• ジェンスクリプト・バイオテック株式会社（中国）
• タカラバイオ株式会社（日本）
• BGIグループ（中国）
• ロシュ・ダイアグノスティックス（スイス）
• Eurofins Scientific (ルクセンブルク)

米国における移植用HLAタイピング市場の最新動向

• 2021年4月、CareDx社はスウェーデンのストックホルムに、次世代シーケンシング（NGS）を用いたHLAタイピングサービスラボを開設しました。このラボでは、AlloSeq Tx17テストを用いた高解像度HLAタイピングを提供し、研究、ワクチンおよび医薬品開発、移植適合性試験を支援しています。この事業拡大は、CareDx社にとって米国以外で初のHLA検査サービスとなり、高度なタイピングサービスへのグローバルなアクセスを拡大するものでした。
• In March 2024, Illumina, Inc. and GenDx announced a strategic partnership to co‑develop next‑generation sequencing (NGS)‑based HLA typing software combining GenDx’s NGSengine with Illumina’s sequencing platforms, aimed at enhancing high‑resolution HLA typing workflows for clinical and research laboratories in the US and Europe
• In May 2024, Thermo Fisher Scientific launched its Ion AmpliSeq HLA Panels v3 optimized for the Genexus Integrated Sequencer, offering improved Class I and Class II HLA coverage and faster turnaround times for transplant laboratories, helping to streamline donor‑recipient compatibility testing
• In October 2024, CareDx, Inc. introduced AlloSeq cfDNA v2, a cell‑free DNA assay that integrates HLA typing with transplant surveillance, enabling clinicians to monitor potential organ rejection and compatibility more effectively and offering enhanced post‑transplant follow‑up capabilities
• In November 2024, DiaSorin S.p.A. updated its xMAP‑based HLA typing panels, expanding Class II allele libraries and providing enhanced mid‑throughput HLA typing solutions tailored for small to mid‑sized transplant centers, improving accuracy and allele coverage
• In September 2024, Immucor unveiled its LIFECODES LifeScreen Deluxe, a high‑resolution antibody screening platform designed to improve the accuracy and speed of donor‑recipient matching in transplant diagnostics, advancing immunogenetic screening capabilities at transplant centers
• In August 2024, Thermo Fisher Scientific received U.S. FDA 510(k) clearance for its SeCore CDx HLA A Sequencing System, approved as a companion diagnostic for TECELRA (afamitresgene autoleucel), enhancing precision HLA typing applications linked to immunotherapies and transplant eligibility

SKU-17321